Aurolife Pharma
US-based pharmaceutical manufacturing company focused on production of generic oral solid dosage products. Operates a US FDA–approved cGMP oral solid dosage facility (100,000 sq ft) undergoing renovation and extension; provides manufacturing, R&D, quality assurance/quality control, regulatory support and drug safety/product complaint handling for the US market. 100% owned subsidiary of Aurobindo Pharma USA Inc.
Industries
Nr. of Employees
medium (51-250)
Aurolife Pharma
Dayton, New Jersey, United States
Services
On-site manufacturing of generic oral solid dosage products in a US-based cGMP facility.
Intake and handling of medical inquiries, adverse drug events, and product complaints via a designated drug safety/product compliance group.
On-site manufacturing of generic oral solid dosage products in a US-based cGMP facility.
Intake and handling of medical inquiries, adverse drug events, and product complaints via a designated drug safety/product compliance group.
Expertise Areas
- Generic pharmaceutical development
- Oral solid dosage manufacturing
- cGMP compliance and regulatory affairs
- Quality assurance and quality control
Key Technologies
- cGMP manufacturing
- Oral solid dosage formulation
- Formulation development
- Manufacturing scale-up and commissioning
News & Updates
An extension to the existing oral solid dosage manufacturing facility was constructed with updated technology; facility renovation and re-opening scheduled for June 2023.
An extension to the existing oral solid dosage manufacturing facility was constructed with updated technology; facility renovation and re-opening scheduled for June 2023.